Project Grant R43AI100376

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $553,248 to The Trustees of the University of Pennsylvania for research on INPP5E signaling and treatment approaches for rheumatoid arthritis (RA). The key objectives are to: 1) investigate how macrophage INPP5E expression impacts inflammation and bone erosion in RA, by analyzing...

This $506,085 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to identify predictive biomarkers for response to biological therapies in patients with rheumatoid arthritis (RA). The primary focus is on evaluating the potential of obesity-induced inflammatory mediators, including proteins (adipokines) and lipids, to predict...

This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the role of Notch signaling in driving synovial fibrogenesis and treatment failure in rheumatoid arthritis (RA). The $529,616 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, supports a 5-year research project to: 1)...

This Project Grant award in the amount of $1,078,081 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The funding supports the development of a novel class of small molecule antagonists to the retinoic acid receptor-alpha (RAR) that can inhibit the gut migration of activated T cells, which is a promising therapeutic approach for inflammatory bowel disease...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) worth $735,372 to Brigham & Women's Hospital Inc. on May 15, 2025. The project, titled "T Cell Expression of Inflammatory Chemokine Receptors," aims to identify transcription factors and cytokines that regulate the expression of chemokine receptors, such as CCR2, CCR5, and CXCR6, on T cells in inflamed...

This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $555,774 to the University of Alabama at Birmingham (UAB) to conduct research aimed at understanding how the Aryl Hydrocarbon Receptor (AhR) pathway can suppress the development of T-bet+ B cells in systemic lupus erythematosus (SLE). The key research objectives are to determine if IL-4 acts through the AhR pathway...

This $1,009,930 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports late-stage development of a sustained-release relaxin formulation for treating joint contracture, specifically shoulder arthrofibrosis. The primary goals are to: 1) perform pilot-scale production of the relaxin drug substance, 2) complete late-stage manufacturing and...

This Project Grant award of $1,305,116 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh supports a cell-based high-throughput screening (HTS) campaign to identify negative allosteric modulators of the leukemia-associated tyrosine kinase BTK. The goal is to develop novel small molecule inhibitors that can disrupt BTK signaling and overcome acquired resistance to current BTK inhibitor drugs like ibrutinib. The research team, which...